This article examines what the current Phase 2 evidence shows, outlines known side effects and safety considerations, and explains the drug's regulatory status in the UK
However, clinicians emphasize that individual responses vary widely, and the effect is not universalsome patients report no change in drinking behavior whatsoever
Free to download 7-day free trial $9.99/month or $59.99/year Irene Astaficheva is a Precision Nutrition Level 1 Certified coach (PN1, PN-SSR), a Certified Women's Coaching Specialist (GGS-1), and holds a postgraduate diploma in Nutrition: Science and Applications
Rybelsus is currently the only oral semaglutide drug on the market
Potential harm to breastfeeding infants is unknown
If you think your pen might have frozen, don't use it